These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
398 related items for PubMed ID: 17958525
1. High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Ziemann M, Krueger S, Maier AB, Unmack A, Goerg S, Hennig H. Transfusion; 2007 Nov; 47(11):1972-83. PubMed ID: 17958525 [Abstract] [Full Text] [Related]
5. Cytomegalovirus (CMV) seroprevalence in Japanese blood donors and high detection frequency of CMV DNA in elderly donors. Furui Y, Satake M, Hoshi Y, Uchida S, Suzuki K, Tadokoro K. Transfusion; 2013 Oct; 53(10):2190-7. PubMed ID: 23968359 [Abstract] [Full Text] [Related]
6. Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Thiele T, Krüger W, Zimmermann K, Ittermann T, Wessel A, Steinmetz I, Dölken G, Greinacher A. Transfusion; 2011 Dec; 51(12):2620-6. PubMed ID: 21645009 [Abstract] [Full Text] [Related]
7. Direct assessment of cytomegalovirus transfusion-transmitted risks after universal leukoreduction. Wu Y, Zou S, Cable R, Dorsey K, Tang Y, Hapip CA, Melmed R, Trouern-Trend J, Wang JH, Champion M, Fang C, Dodd R. Transfusion; 2010 Apr; 50(4):776-86. PubMed ID: 19912585 [Abstract] [Full Text] [Related]
8. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Seed CR, Piscitelli LM, Maine GT, Lazzarotto T, Doherty K, Stricker R, Stricker R, Iriarte B, Patel C. Transfusion; 2009 Jan; 49(1):134-45. PubMed ID: 18954407 [Abstract] [Full Text] [Related]
9. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study. Narvios AB, Lichtiger B. Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531 [Abstract] [Full Text] [Related]
10. Transfusion-transmitted cytomegalovirus: behaviour of cell-free virus during blood component processing. A study on the safety of labile blood components in Switzerland. Voruz S, Gowland P, Eyer C, Widmer N, Abonnenc M, Prudent M, Masouridi-Levrat S, Duchosal MA, Niederhauser C. Blood Transfus; 2020 Nov; 18(6):446-453. PubMed ID: 32203012 [Abstract] [Full Text] [Related]
11. Survey of current practice for prevention of transfusion-transmitted cytomegalovirus in the United States: leucoreduction vs. cytomegalovirus-seronegative. Smith D, Lu Q, Yuan S, Goldfinger D, Fernando LP, Ziman A. Vox Sang; 2010 Jan; 98(1):29-36. PubMed ID: 19695013 [Abstract] [Full Text] [Related]
12. Infectivity of blood products containing cytomegalovirus DNA: results of a lookback study in nonimmunocompromised patients. Ziemann M, Juhl D, Brockmann C, Görg S, Hennig H. Transfusion; 2017 Jul; 57(7):1691-1698. PubMed ID: 28370032 [Abstract] [Full Text] [Related]
19. Prevalence of cytomegalovirus antibody in Thai-northeastern blood donors. Urwijitaroon Y, Teawpatanataworn S, Kitjareontarm A. Southeast Asian J Trop Med Public Health; 1993 Jul; 24 Suppl 1():180-2. PubMed ID: 7886568 [Abstract] [Full Text] [Related]
20. Surveillance of cytomegalovirus (CMV) DNAemia in pediatric allogeneic stem cell transplantation: incidence and outcome of CMV infection and disease. Bordon V, Bravo S, Van Renterghem L, de Moerloose B, Benoit Y, Laureys G, Dhooge C. Transpl Infect Dis; 2008 Feb; 10(1):19-23. PubMed ID: 17511814 [Abstract] [Full Text] [Related] Page: [Next] [New Search]